Data from a phase II study evaluating MDT for oligorecurrent PC showed a trend toward improved ADT‐free survival at 3 years’ follow‐up (median ADT‐free survival) was 13 months (80% CI, 12‐17 months) for the surveillance group and 21 months (80% CI, 14‐29 months) for the MDT group (HR, 0.60 [80% CI, 0.40‐0.90]; P = .11).
← all excerpts
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
1
—
—